Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics Incorporated

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R...

Citi Names 2 Biotech Stocks ‘Top Picks’ for 2026

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Cytokinetics today and set a price target of $75.85. Skor covers the Healthcare sect...

Morgan Stanley Sticks to Its Buy Rating for Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX), Strata Critical M...

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Strata Critical Medical (SRTA) and Cytokinetics (CYTK)

Cytokinetics ( ($CYTK) ) has shared an announcement. On May 5, 2026, Cytokinetics released an updated corporate presentation outlining the commerci...

Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Disc Medicine (IRON) and Cytokineti...

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Disc Medicine (IRON) and Cytokinetics (CYTK)

Traders will find the top stock market stories for Tuesday in our daily roundup.


Morning News Wrap-Up, 5/5/26: Today’s Biggest Stock Market Stories!

Cytokinetics stock was up on Tuesday after a Phase 3 clinical trial met its primary endpoints.


This Is Why Cytokinetics Stock (CYTK) Soared Today

Insiders have been trading these 5 stocks: (($WU)), (($CYTK)), (($FIX)), (($ACI)) and (($ASX)). Here is a breakdown of their recent trades and thei...

Current Quarter	$-1.63	Next Quarter	$-1.62
Current Year	$-6.27	Next Year	$-4.58
QoQ Growth	+0.6%	YoY Growth	+27.0%
3Y EPS CAGR	-14.7%	Target Price	$103.10
Consensus	Buy	Upside	+35.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CYTK	$76.29	-0.84%	1.65M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CYTK	$76.29	-0.8%	1.65M
3
4
5
6

CYTK

CYTK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cytokinetics Incorporated Data in Excel

Get Cytokinetics Incorporated Data in Excel